Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 539997 | NSE Symbol : | ISIN : INE552U01010 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
20-Jan-2025	31-Jan-2025	Quarterly Results	Quarterly Results Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine months ended December 31, 2024 along with Limited Review Report (As Per BSE Announcement dated on 20.01.2025) Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform your that Board of Directors in its meeting held today i.e., January 31, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024 (As per BSE Announcement Dated on 31/01/2025)
22-Oct-2024	30-Oct-2024	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year e UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024 (As Per BSE Announcement dated on 30.10.2024)
02-Aug-2024	10-Aug-2024	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June 2024. We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended as on 30.06.2024 along with the Auditors limited review reports thereon. (As Per BSE Announcement Dated on: 10/08/2024) Revised Results for Q. E. 30-06-2024 are attached herewith after correction of minor typographical error. This will have no effect on the figures of financial results of the company declared for q.e. 30-06-2024. (As Per Bse Announcement Dated on 12.08.2024)
08-May-2024	23-May-2024	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 inter alia to consider and approve the Standalone & Consolidated audited financial results for the fourth quarter and financial year ended on 31st March 2024.Further as per our earlier communication vide our letter dated 30th March 2024 and in accordance with the Companys Code of Conduct for Prohibition of Insider Trading framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the Trading window for dealing in Securities of the Company for all the Board of Directors Designated Persons and their immediate relatives will remain closed till 48 hours after the financial results of the Company are made public on May 23 2024.This is for your information and record. AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2024 ALONGWITH OTHER NECESSARY ANNEXURES ARE ATTACHED HEREWITH We wish to inform you that at the Board Meeting held today i.e. on Thursday, May 23, 2024, the Board of Directors of the Company have inter alia Considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year Ended 31st March, 2024. we are enclosing herewith: a. Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year Ended 31st March, 2024. b. Statement of Assets and Liabilities as at March 31, 2024 and Statement of Cash Flows for the Financial Year Ended 31st March, 2024. c. Declaration pursuant to Regulation 33(3) (d) of the SEBI (LODR) Regulations, 2015, regarding unmodified opinion of the Statutory Auditors on the Annual Financial Results for the Financial Year ended on 31st March, 2024. d. Auditors reports on the Audited Financial Results on Standalone and Consolidated basis. (As Per BSE Announcement Dated on 23/05/2024)
25-Jan-2024	06-Feb-2024	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine months ended December 31 2023 along with Limited Review Report. Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform you that Board of Directors in its meeting held today i.e., February 06, 2024, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2023 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. Submission of Unaudited financial results for the quarter and nine months ended 31-12-2023 (As per BSE Announcement Dated on 06/02/2024)
17-Oct-2023	04-Nov-2023	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30 2023. Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform your that Board of Directors in its meeting held today i.e., November 04, 2023, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2023, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30-09-2023 (As per BSE Announcement Dated on 04/11/2023) NEWSPAPER PUBLICATIONS OF FINANCIAL RESULTS FOR Q.E. 30-09-2023 (As Per BSE Announcement Dated on 10/11/2023)
06-Sep-2023	06-Sep-2023	AGM	Outcome of Board meeting held on September 06, 2023 This is to inform you under Regulation 30 and any other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Board of Directors of the Company at its meeting held today i.e. Wednesday, September 06, 2023 inter-alia has taken the following decisions
01-Aug-2023	10-Aug-2023	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June 2023. Unaudited financial results for q.e. 30.06.2023 as approved by Board of Directors in their meeting held on 10-08-2023 are enclosed herewith. (As per BSE Announcement Dated on 10/08/2023)
18-May-2023	27-May-2023	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2023 inter alia to consider and approve the standalone & consolidated audited financial results for the fourth quarter and financial year ended on 31st March 2023.Further as per our earlier communication vide our letter dated 30th March 2023 and in accordance with the Companys Code of Conduct for Prohibition of Insider Trading framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the Trading window for dealing in securities of the company for all the Board of Directors Designated Persons and their immediate relatives will remain closed till 48 hours after the financial results of the company are made public on May 27 2023. we wish to inform you that at the Board Meeting held today i.e. on Saturday, May 27, 2023, the Board of Directors of the Company have inter alia considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year Ended 31st March, 2023. The said Audited Financial Results were reviewed by the Audit Committee and thereafter approved by the Board of Directors. (As Per BSE Announcement Dated on 27.05.2023)
07-Feb-2023	14-Feb-2023	Quarterly Results	Quarterly Results Pursuant to Regulation 30 & 33 read with clause 4(h) of Para A, Part A of Schedule III of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') this is to inform you that Board of Directors in its meeting held today i.e., 14th February, 2023, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. Pursuant to Regulation 30 & 33 read with clause 4(h) of Para A, Part A of Schedule III of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') this is to inform you that Board of Directors in its meeting held today i.e., 14th February, 2023, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. (As Per BSE Announcement Dated on 14.02.2023)
07-Nov-2022	14-Nov-2022	Quarterly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30 2022 Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform your that Board of Directors in its meeting held today i.e., November 14, 2022, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2022, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform your that Board of Directors in its meeting held today i.e., November 14, 2022, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2022, along with Limited Review Report issued by Statutory Auditors of the Company. (As Per BSE Announcement Dated on 14/11/2022) As per the requirement of Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), enclosed herewith is the copy of the Newspaper Publication of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2022 published in the newspaper viz. Financial Express (English) and Punjabi Jagran (Punjabi) on 16th November, 2022. (As Per BSE Announcement Dated on 16/11/2022)
06-Sep-2022	06-Sep-2022	AGM	The following matters were decided by the board: 1. The Board of directors of the company have considered and approved the Report of Board of Directors under Section 134 of the Companies Act, 2013 for the year ended 31st March, 2022. 2.The Board of directors of the company have considered and approved the Notice of 39th Annual General Meeting of the Company. 3. Date, Time and Place of the 39thAnnual General Meeting has been fixed. 4. Dates of Book Closure for the purpose of 39th Annual General Meeting has been fixed and approved by the Board. 5. Considered and approved E-voting facility: E-voting facility for the Shareholders shall commence from 27th September, 2022 at 9:00 A.M. to 29th September, 2022, 5:00 P.M. 6. Considered and approved Mr. Rishi Mittal, Practicing Company Secretary as Scrutinizer for 39th Annual General Meeting to held on 30th September, 2022.
04-Aug-2022	13-Aug-2022	Quarterly Results	Quarterly Results With respect to captioned subject, we wish to inform you that the Board of Directors in its Meeting held today has inter-alia, considered and approved the standalone and consolidated Un-Audited Financial Results for the quarter ended June 30, 2022. We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended on 30.06.2022 along with the limited review reports thereon. (As Per BSE Announcement Dated on 13/08/2022)
04-Aug-2022	04-Aug-2022	Change in Directors	Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on Thursday 04th August, 2022, has considered and approved the appointment of Mr. Sachin Seth (DIN: 00466950) as an Additional Director (Non-Executive and Non-Independent) of the Company w.e.f. 04th August, 2022 subject to the approval of shareholders in forthcoming annual general meeting of the Company. Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on Thursday 04th August, 2022, has considered and approved the appointment of Mr. Sachin Seth (DIN: 00466950) as an Additional Director (Non-Executive and Non-Independent) of the Company w.e.f. 04th August, 2022 subject to the approval of shareholders in forthcoming annual general meeting of the Company.
18-May-2022	28-May-2022	Half Yearly Results	Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve Pursuant to regulation 29 of the SEBI (Listing obligations and disclosure requirements) Regulations 2015 we hereby inform the stock exchange that the meeting of board of directors of the company is scheduled to be held on Saturday May 28 2022 at 5:00 p.m. at VILLAGE NAGKALAN MAJITHA ROAD AMRITSAR to consider and approve the standalone & consolidated audited financial results for the half year and financial year ended on 31st March 2022. We would like to inform you that at the Board Meeting held today i.e. on Saturday, May 28, 2022, the Board of Directors of the Company have inter alia considered and approved the Audited Standalone and Consolidated Financial Results for the Half Year/ Year Ended 31st March, 2022. Pursuant to Regulation 33 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith: a. Audited Standalone Financial Results for the Half Year and Year Ended 31st March, 2022. b. Audited Consolidated Financial Results for the Half Year and Year Ended 31st March, 2022. c. Declaration pursuant to Regulation 33(3) (d) of the SEBI (LODR) Regulations, 2015, d. Auditors reports on the Audited Financial Results on Standalone and Consolidated basis. (As Per BSE Announcement Dated on 28/05/2022)

1 2

LOGIN HERE

Kwality Pharmaceuticals Ltd

Board Meeting